Matches in Nanopublications for { ?s ?p "[Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP276946.RAS_Yn8GY1QgTqP6_aBkA_KJDHObvlyggV6GiOVTcQvVI130_assertion description "[Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP276946.RAS_Yn8GY1QgTqP6_aBkA_KJDHObvlyggV6GiOVTcQvVI130_provenance.
- NP632830.RA0RczjPjtF5u4HPDWVVTvNeq8sRZ2tOeR9o14nPZGAAU130_assertion description "[Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP632830.RA0RczjPjtF5u4HPDWVVTvNeq8sRZ2tOeR9o14nPZGAAU130_provenance.